See more : Yduqs Participações S.A. (YDUQ3.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Theravance Biopharma, Inc. (TBPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Theravance Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Renaissance Global Limited (RGL.BO) Income Statement Analysis – Financial Results
- Gree Real Estate Co., Ltd (600185.SS) Income Statement Analysis – Financial Results
- Nutanix, Inc. (0K9O.L) Income Statement Analysis – Financial Results
- The Westaim Corporation (WEDXF) Income Statement Analysis – Financial Results
- NTT DATA Corporation (NTDTY) Income Statement Analysis – Financial Results
Theravance Biopharma, Inc. (TBPH)
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.42M | 51.35M | 55.31M | 71.86M | 73.41M | 60.37M | 15.39M | 48.65M | 42.13M | 11.69M | 226.00K | 130.15M | 14.85M |
| Cost of Revenue | 40.62M | 6.59M | 7.29M | 260.95M | 219.25M | 715.00K | 6.03M | 2.89M | 4.66M | 4.06M | 120.58M | 114.00M | 3.84M |
| Gross Profit | 16.80M | 44.76M | 48.03M | -189.10M | -145.83M | 59.66M | 9.36M | 45.75M | 37.47M | 7.63M | -120.35M | 16.15M | 11.01M |
| Gross Profit Ratio | 29.26% | 87.17% | 86.83% | -263.16% | -198.65% | 98.82% | 60.81% | 94.05% | 88.95% | 65.28% | -53,253.54% | 12.41% | 74.12% |
| Research & Development | 40.62M | 63.39M | 193.66M | 260.95M | 219.25M | 201.35M | 173.89M | 141.71M | 129.17M | 168.52M | 120.58M | 114.00M | 98.85M |
| General & Administrative | 65.00M | 59.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 5.10M | 8.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 70.10M | 67.07M | 99.30M | 108.66M | 106.08M | 97.06M | 95.59M | 84.51M | 90.20M | 71.65M | 35.93M | 25.73M | 21.50M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -1.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 113.46M | 130.47M | 292.95M | 369.61M | 325.33M | 298.41M | 269.48M | 226.22M | 219.37M | 240.17M | 156.51M | 139.72M | 120.35M |
| Cost & Expenses | 113.46M | 130.47M | 292.95M | 369.61M | 325.33M | 299.12M | 275.51M | 229.12M | 224.03M | 244.23M | 156.51M | 139.72M | 124.19M |
| Interest Income | 9.12M | 8.55M | 1.11M | 2.83M | 8.40M | 11.97M | 4.96M | 1.31M | 631.00K | 1.87M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.35M | 6.37M | 46.89M | 44.59M | 31.86M | 10.48M | 8.55M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.05M | 6.59M | 7.29M | 6.64M | 6.52M | 3.17M | 4.03M | 3.12M | 2.99M | 2.66M | 2.65M | 3.25M | 3.84M |
| EBITDA | -40.87M | -79.86M | -249.39M | -294.00M | -203.29M | -212.44M | -259.14M | -176.04M | -178.77M | -228.01M | -153.63M | -6.32M | -105.49M |
| EBITDA Ratio | -71.17% | -137.45% | -239.64% | -315.19% | -285.80% | -357.14% | -1,658.42% | -368.27% | -424.70% | -1,989.55% | -67,978.32% | -4.86% | -710.19% |
| Operating Income | -56.04M | -91.96M | -257.78M | -297.76M | -251.92M | -238.75M | -260.12M | -180.47M | -181.90M | -232.54M | -156.28M | -9.58M | -109.34M |
| Operating Income Ratio | -97.58% | -179.09% | -466.06% | -414.37% | -343.14% | -395.48% | -1,690.65% | -370.96% | -431.80% | -1,989.55% | -69,152.21% | -7.36% | -736.06% |
| Total Other Income/Expenses | 6.77M | -858.00K | -7.44M | 11.22M | 10.24M | 12.67M | -11.59M | -92.00K | 631.00K | 1.87M | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -49.27M | -92.82M | -199.58M | -286.54M | -241.68M | -226.09M | -271.71M | -180.56M | -181.27M | -230.67M | -156.28M | -9.58M | -109.34M |
| Income Before Tax Ratio | -85.80% | -180.76% | -360.83% | -398.76% | -329.20% | -374.50% | -1,765.96% | -371.15% | -430.30% | -1,973.60% | -69,152.21% | -7.36% | -736.06% |
| Income Tax Expense | 5.92M | 9.00K | -151.00K | -8.52M | -5.22M | -10.56M | 13.69M | 10.11M | 951.00K | 6.36M | 0.00 | 0.00 | 0.00 |
| Net Income | -55.19M | -92.82M | -199.43M | -278.02M | -236.46M | -215.52M | -285.41M | -190.67M | -182.22M | -237.04M | -156.28M | -9.58M | -109.34M |
| Net Income Ratio | -96.11% | -180.78% | -360.55% | -386.90% | -322.08% | -357.01% | -1,854.97% | -391.94% | -432.56% | -2,028.05% | -69,152.21% | -7.36% | -736.06% |
| EPS | -1.00 | -1.26 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 | -4.92 | -0.30 | -3.43 |
| EPS Diluted | -1.00 | -1.26 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 | -4.84 | -0.30 | -3.43 |
| Weighted Avg Shares Out | 55.30M | 73.59M | 69.46M | 62.35M | 55.61M | 53.97M | 52.35M | 44.71M | 34.15M | 31.76M | 31.74M | 31.74M | 31.90M |
| Weighted Avg Shares Out (Dil) | 55.30M | 73.59M | 69.46M | 62.35M | 55.61M | 53.97M | 52.35M | 44.71M | 34.15M | 31.76M | 32.26M | 32.26M | 31.90M |
Invest Alongside Wall Street Legend Seth Klarman: 2 New Stocks He Bought and 1 He Dumped
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?
Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
Theravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call Transcript
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024
Best Momentum Stocks to Buy for July 15th
Source: https://incomestatements.info
Category: Stock Reports